Risk Factors of Proteinuria in Patients with Hepatocellular Carcinoma Receiving Lenvatinib

Ikesue, Hiroaki; Yamamoto, Haruna; Hirabatake, Masaki; Hashida, Tohru; Chung, Hobyung; Inokuma, Tetsuro; Muroi, Nobuyuki

doi:10.1248/bpb.b21-00913

Cited by 4 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been reported that patients with mCRC are more likely to develop proteinuria than those with other malignancies 23 , 24 . Baseline preexisting proteinuria has been associated with symptom exacerbation following treatment with anti-VEGF agents 14 – 16 , 18 . However, given that the mCRC treatment strategy differs from that of other malignancies evaluated in previous reports 14 – 16 , 18 , 19 , it is crucial to evaluate the impact of baseline preexisting proteinuria on regorafenib-induced symptoms considering prior anti-VEGF treatment.…”

Section: Discussionmentioning

confidence: 99%

“…Baseline preexisting proteinuria has been associated with symptom exacerbation following treatment with anti-VEGF agents 14 – 16 , 18 . However, given that the mCRC treatment strategy differs from that of other malignancies evaluated in previous reports 14 – 16 , 18 , 19 , it is crucial to evaluate the impact of baseline preexisting proteinuria on regorafenib-induced symptoms considering prior anti-VEGF treatment. Thus, we aimed to evaluate the influence of baseline preexisting proteinuria on regorafenib-induced problematic symptoms during real-world mCRC therapy.…”

Section: Discussionmentioning

confidence: 99%

“…The patients were divided into two groups: a control group without baseline proteinuria from May 2013 to May 2022 and a preexisting proteinuria group, including patients with baseline grade 1–2 symptoms from May 2013 to August 2023. We hypothesized that the incidence of defined proteinuria (grade ≥ 2 symptoms for baseline grade 0–1 patients, grade ≥ 3 symptoms in case of baseline grade 2 patients) would be 30% in a control group and 60% in a preexisting proteinuria group, with a patient ratio of 3:2, based on previous reports and our clinical experience 2 , 14 – 16 , 18 . To achieve 80% power with an alpha error of 5%, the required sample size was 60 patients in the control group and 40 patients in the preexisting proteinuria group.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Impact of preexisting proteinuria on the development of regorafenib-induced problematic proteinuria in real-world metastatic colorectal cancer treatment

Saito,

Takekuma,

Komatsu

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Regorafenib is the first multikinase inhibitor for treating metastatic colorectal cancer (mCRC). Proteinuria is a frequently encountered adverse effect, regardless of prior administration of vascular endothelial growth factor inhibitors. Herein, we aimed to assess the impact of baseline preexisting proteinuria on regorafenib-induced problematic proteinuria during real-world mCRC therapy. Patients with mCRC receiving regorafenib (n = 100) were retrospectively assessed and divided into control and preexisting proteinuria (baseline grade of 1–2) groups. The primary endpoint was the development of grade ≥ 2 (grade ≥ 3 in case of baseline grade 2 patients) proteinuria. Propensity score-matching was performed to confirm the robustness of primary analyses. Defined proteinuria occurred in 30.7 and 57.9% of patients in the control and preexisting proteinuria groups, respectively, with significant differences in the all-patient population (P = 0.01). The preexisting proteinuria group exhibited significant defined proteinuria development within 7 days of regorafenib initiation, grade ≥ 3 symptoms, and treatment suspension owing to proteinuria. Similar results were obtained in the propensity score-matched population. According to multivariate logistic regression analysis, baseline proteinuria was a singular risk factor for defined proteinuria development (adjusted odds ratio; 3.76, 95% confidence interval; 1.45–9.75, P = 0.007). Collectively, our study revealed that patients with preexisting proteinuria develop regorafenib-induced proteinuria degradation.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Impact of preexisting proteinuria on the development of regorafenib-induced problematic proteinuria in real-world metastatic colorectal cancer treatment

Saito,

Takekuma,

Komatsu

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“…The CTCAE system is a product of the US National Cancer Institute (NCI). It has been widely used in many clinical trials, extending beyond oncology and encoding their observations based on the CTCAE system ( 15 ).…”

Section: Methodsmentioning

confidence: 99%

“…It uses a range of grades from 1 to 5. Still, specific conditions such as dysgeusia are graded on a five-point scale: 0, absence of mucositis, grade 1 (Asymptomatic or mild), 2 (Presence of moderate pain and ulceration, without interference with food intake), 3 (severe pain with interference with food intake) or 4 (Life-threatening with the need for urgent intervention) ( 15 ).…”

Section: Methodsmentioning

confidence: 99%

Risk factors for oral mucositis in patients with solid tumors under treatment with cetuximab: a retrospective cross-sectional study

Martins,

Borges,

Malta

et al. 2024

Med Oral

View full text Add to dashboard Cite

Background This study retrospectively analyzed the risk factors for oral mucositis (OM) during cetuximab treatment. Material and Methods We screened patients using cetuximab and retrospectively evaluated the presence of OM based on medical records. We collected information from 2 years of evaluations. Patient medical records were reviewed to obtain data on chemotherapy cycle and dose, sex, age, primary tumor, TNM stage, and head and neck radiotherapy (HNR) history. The X2 test and multinomial logistic regression were used for statistical analysis (SPSS 20.0, p < 0.05). Results Among 1831 patients, OM was showed in 750 in any grade (41%), during cetuximab treatment. Most patients were female ( n =944, 51.6%), <70years-old ( n =1149, 62.8%), had larynx cancer ( n =789, 43.1%) in T4 ( n =579, 47.7%), N0 ( n =509, 52.6%) stages. Primary tumor surgery was performed in 1476 (80.6%) patients, radiotherapy in 606 (33.1%) patients and cetuximab protocols most used involved up to four cycles ( n =1072, 58.5%) of <400mg ( n =996, 54.4%) cetuximab doses. Female (OR [odds ratio] = 2.17, CI95% = 1.26-3.75), >70 years-old patients (OR = 16.02, CI95% = 11.99-21.41), with HHNR (OR = 1.84, 1.41-2.40), treated with >4 cycles (OR = 1.52, CI95% = 1.16-2.01) and high doses of cetuximab (OR = 3.80, CI95% = 2.52-5.71) are the greatest risk factors for OM. Conclusions Since the clinical benefit of cetuximab in the treatment of older patients is limited and there is a high OM, especially in women with head and neck treated with radiotherapy, high doses and a high number of cetuximab cycles must be administered with caution. Key words: Mucositis, cetuximab, antibodies, neoplasm, antineoplastic agents.

show abstract

Machine learning application identifies plasma markers for proteinuria in metastatic colorectal cancer patients treated with Bevacizumab

Yu,

Xu,

Feng

et al. 2024

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

Risk Factors of Proteinuria in Patients with Hepatocellular Carcinoma Receiving Lenvatinib

Cited by 4 publications

References 26 publications

Impact of preexisting proteinuria on the development of regorafenib-induced problematic proteinuria in real-world metastatic colorectal cancer treatment

Impact of preexisting proteinuria on the development of regorafenib-induced problematic proteinuria in real-world metastatic colorectal cancer treatment

Risk factors for oral mucositis in patients with solid tumors under treatment with cetuximab: a retrospective cross-sectional study

Machine learning application identifies plasma markers for proteinuria in metastatic colorectal cancer patients treated with Bevacizumab

Contact Info

Product

Resources

About